(PDF) P1.01-95 Crizotinib Treatment in 29 Advanced NSCLC

P1.01-95 Crizotinib Treatment in 29 Advanced NSCLC Chinese Patients With ROS1 Rearrangement——A Single Chinese Cancer Institute Experience

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.651

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

P1.01-30 Crizotinib in Advanced Non-Adenocarcinoma, NSCLC (NA-NSCLC) Patients With ALK Rearrangement: A Retrospective Study and Literature Review

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-29 Crizotinib in Advanced Lung Adenocarcinoma Patients With ALK or ROS-1 Rearrangement: Is It the Same?

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-106 Pembrolizumab Randomized, Phase 1 Study in Chinese Patients With Advanced NSCLC: KEYNOTE-032

Journal of Thoracic Oncology

Respiratory Medicine

English

Clinicopathological Features and Clinical Efficacy of Crizotinib in Chinese Patients With ROS1‑positive Non‑small Cell Lung Cancer

Oncology Letters

Cancer Research

English

P1.01-112 Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

P2.04-29 Preliminary Results With Tislelizumab in Chinese Patients With Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology

Respiratory Medicine

English

Prevalence of ROS1 Fusion in Chinese Patients With Non-Small Cell Lung Cancer

Thoracic Cancer

Respiratory Medicine

English

P1.01-45 Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience From Turkey

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-39 Cost-Effectiveness of Crizotinib Versus Chemotherapy as First-Line Treatment of ALK Positive Advanced NSCLC -- A Real World Study

Journal of Thoracic Oncology

Respiratory Medicine

English